Wechselwirkungen · Brilique
Brilique 90 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 28
HOS-123577 · Präparat HOS-095701
CYP3A inducers Co-administration of rifampicin with ticagrelor decreased ticagrelor Cmax and AUC by 73% and 86%, respectively. The Cmax of the active metabolite was unchanged and the AUC was decreased by 46%, respectively. Other CYP3A inducers (e.g. phenytoin, carbamazepine and phenobarbital) would be expected to decrease the exposure to ticagrelor as well. Co-administration of ticagrelor with potent CYP3A inducers may decrease exposure and efficacy of ticagrelor, therefore, their concomitant use with ticagrelor is discouraged.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T10:59:00Z · SHA-256 f815638059a70571d33a6ddc4107523f2ae567aafc2b20551ad4a9b0fb2f2aca · Passage 2e668d79b54c473c475a3361cf15876eebdf30dd296c2f0bbbfcbf8ec3d34885 · Zeichen 1574–2107 im Abschnitt